MedPath

Detoxification and Treatment of Subjects With Medication Overuse Headache

Phase 4
Conditions
Analgesic Rebound Headache
Registration Number
NCT00432549
Lead Sponsor
The New England Center for Headache, P.C.
Brief Summary

The purpose of this study is to assess the benefits of almotriptan used as a transitional therapy and topiramate in subjects with medication overuse headaches (MOH.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Medication overuse headaches 18 years of age and older Must have a diagnosis of probable medication overuse headache Must have greater than fifteen headache days per month Must be in generally good health Female subjects must be postmenopausal or practicing an acceptable method of birth control
Exclusion Criteria
  • Not overusing six or more tablets per day of compounds containing barbituates opioids No overuse of triptans Previous failure or side effects with topiramate or almotriptan Cannot be pregnant or lactating

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Primary measure for the detoxification period
Number of days with mild or no pain in the first two weeks of treatment
Primary for the prevention of relapse
Pain free days through day ninety
Secondary Outcome Measures
NameTimeMethod
Headache frequency through day ninety
Primary measure for the detoxification period
Number of days without any headache in the first two weeks of treatment
Primary for the prevention of relapse

Trial Locations

Locations (1)

The New England Center for Headache, P.C.

🇺🇸

Stamford, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath